Discontinued — last reported Q1 '25
Royalty — Total revenues
Neurocrine Biosciences Royalty — Total revenues increased by 81.1% to $6.7M in Q1 2025 compared to the prior quarter. Year-over-year, this metric grew by 123.3%, from $3M to $6.7M. Over 3 years (FY 2021 to FY 2024), Royalty — Total revenues shows a downward trend with a -15.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market adoption and commercial success of the licensed products, while a decrease suggests declining sales or the expiration of patent protections.
Detailed definition
This metric represents the aggregate revenue recognized from royalty-based licensing agreements where the company grants...
Peer comparison
Commonly reported by biotech and pharmaceutical firms as 'Royalty Revenue' or 'Licensing Revenue' and is benchmarked against the commercial performance of the partner's product portfolio.
nbix_segment_royalty_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.9M | $5.9M | $6M | $4.2M | $5.2M | $6.1M | $5.7M | $3.7M | $4.2M | $4.2M | $4.7M | $3M | $3.5M | $3.3M | $3.7M | $6.7M |
| QoQ Change | — | +0.0% | +1.7% | -30.0% | +23.8% | +17.3% | -6.6% | -35.1% | +13.5% | +0.0% | +11.9% | -36.2% | +16.7% | -5.7% | +12.1% | +81.1% |
| YoY Change | — | — | — | — | -11.9% | +3.4% | -5.0% | -11.9% | -19.2% | -31.1% | -17.5% | -18.9% | -16.7% | -21.4% | -21.3% | +123.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's royalty — total revenues?
- Neurocrine Biosciences (NBIX) reported royalty — total revenues of $6.7M in Q1 2025.
- How has Neurocrine Biosciences's royalty — total revenues changed year-over-year?
- Neurocrine Biosciences's royalty — total revenues increased by 123.3% year-over-year, from $3M to $6.7M.
- What is the long-term trend for Neurocrine Biosciences's royalty — total revenues?
- Over 3 years (2021 to 2024), Neurocrine Biosciences's royalty — total revenues has grown at a -15.4% compound annual growth rate (CAGR), from $22.3M to $13.5M.
- What does royalty — total revenues mean?
- Total income earned from licensing intellectual property to other companies based on their product sales.